Back

Evaluating respiratory syncytial virus immunization strategies for infants in Canada: a cost-utility analysis

2026-01-11 health economics Title + abstract only
View on medRxiv
Show abstract

BackgroundRespiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections and hospitalizations among infants in Canada. New long-acting monoclonal antibodies (mAbs) and vaccines administered during pregnancy have expanded prevention options, yet the most cost-effective immunization program remains uncertain. MethodsWe updated a Canadian cost-utility model to evaluate seven seasonal RSV prevention strategies over one year (with a lifetime horizon for mortality impacts)...

Predicted journal destinations